X4 Pharmaceuticals
XFOR
52 hedge funds and large institutions have $60.1M invested in X4 Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 13 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
13% more call options, than puts
Call options by funds: $271K | Put options by funds: $239K
3% more capital invested
Capital invested by funds: $58.3M → $60.1M (+$1.82M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.24% less ownership
Funds ownership: 1.9% → 1.66% (-0.24%)
7% less funds holding
Funds holding: 56 → 52 (-4)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$9.18M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$8.23M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$3.76M |
| 4 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$3.4M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.99M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.71M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$428K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$347K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$238K |
XFOR Hedge Fund Activity: Q4 2022 in Review
52 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2022, worth a combined $60.1M — up 3.1% from $58.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of XFOR and 11 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 19 added.
The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $9.18M. The largest seller was Point72 Asset Management, cutting an estimated $2.99M.
- 52 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2022, down from 56 in Q3 2022.
- Funds reported $60.1M of X4 Pharmaceuticals stock for Q4 2022, up 3.1% quarter-over-quarter.
- 11 funds opened new X4 Pharmaceuticals positions in Q4 2022 and 13 closed out, a net change of -2 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2022 was Bain Capital Life Sciences Investors, an estimated $9.18M added.
- The largest X4 Pharmaceuticals seller in Q4 2022 was Point72 Asset Management, an estimated $2.99M sold.
Based on aggregated 13F filings for Q4 2022.